Financials
Financial year 2023
Worth noting
- A loss two years in a row.
Gross margin
€ -763,895
▲ 48% vs 2022
Profit
Caution€ -2.8 million
▲ 16% vs 2022
Debts
Low€ 1.4 million
▲ 169% vs 2022
FOx Biosystems from Diepenbeek, company number BE0653744366, closed financial year 2023 with a result of € -2.8 million after tax. For that financial year FOx Biosystems recorded a gross margin of € -763,895 and equity of € 1.3 million. Compared with financial year 2022, the result moved from € -3.3 million to € -2.8 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2024.
What happened at FOx Biosystems?
What happened at FOx Biosystems in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Heran Partners BV stepped down as director. NBB
- Bart Geers stepped down as director. NBB
- LRM Beheer BV stepped down as director. NBB
- Jeroen Lammertyn stepped down as director. NBB
- Jerry Williamson stepped down as director. NBB
- Mark Truesdale stepped down as director. NBB
- Filip Delport stepped down as director. NBB
- New annual accounts for financial year 2023: loss of € 2.8 million. Source: NBB ↗
In short
From € 2.3 million loss in 2021 to € 2.8 million loss in 2023.
Paid € 18,798 in corporate taxes since 2021.
A new publication or filing at FOx Biosystems? We notify you, reason included.
Follow FOx BiosystemsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of Fox Biosystems Ltd itself.
Directors
According to the 2023 annual accounts
Director · represented by Thomas van Elzakker
since 2020 · until 2023
Director · represented by Kathleen Vandersmissen
Also active at: Lynxcare Clinical Informatics, ASPECT ANALYTICS, Heran HealthTech Fund I +5 more
since 2020 · until 2030
since 2019 · until 2030
Director · represented by Dries Bauters
Also active at: H.W.P., Corda Campus, MIJNSCHADE EN BEMALING LIMBURGS MIJNGEBIED +38 more
since 2019 · until 2030
Jeroen Lammertyn
Director
since 2019 · until 2030
Jerry Williamson
Director
since 2024 · until 2030
Mark Truesdale
Director
since 2023 · until 2030
Filip Delport
Director
since 2019 · until 2030
Establishments
Establishment units
Physical locations of this company
Agoralaan Abis
3590 Diepenbeek
Bollebergen 2b
9052 Gent
Active since 13 February 2023
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 14 companies are registered at this address.
Clinitude
€ 419,430 gross margin · 2025
Highstar Engineering
€ -41,079 gross margin · 2024
IDEA FAMILY
€ -3,258 gross margin · 2025
BIOKEY
€ -25,987 gross margin · 2025
BIOSTRAND
€ -2.1 million gross margin · 2025
+9 more
Details
- Company number
- 0653.744.366
- VAT number
- BE 0653.744.366
- Registered office
- Agoralaan Abis, 3590 Diepenbeek
- Names & denominations
- FOx Biosystems
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Opening faillissement
- Start date
- 3 May 2016
- Peppol
- Not registered
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Overige gespecialiseerde wetenschappelijke en technische activiteiten
Adviesbureaus op het gebied van public relations en communicatie